Early postoperative erythromycin breath test correlates with hepatic cytochrome P4503A activity in liver transplant recipients

Clinical Pharmacology and Therapeutics

Volumn 70, Issue 5, 2001, Pages 446-454

  Schmidt, Lars E ^b   Olsen, Anette Kristensen ^a,b,c   Stentoft, Karen ^a,b,c   Rasmussen, Allan ^a,b,c   Kirkegaard, Preben ^a,b,c   Dalhoff, Kim ^a,b,c  

^a Department of Hepatology A Transplantation V ^*  (Denmark)

^b Rigshospitalet   (Denmark)

^c NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; CYTOCHROME P450 3A4; ERYTHROMYCIN; IMMUNOSUPPRESSIVE AGENT; TACROLIMUS;

ADULT; AGED; ARTICLE; BREATH ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DEMETHYLATION; ENZYME ACTIVITY; ENZYME ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIVER BIOPSY; LIVER TRANSPLANTATION; MALE; OPTICAL DENSITY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; WESTERN BLOTTING;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; ARYL HYDROCARBON HYDROXYLASES; BREATH TESTS; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; ERYTHROMYCIN; FEMALE; HUMANS; LIVER; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; OXIDOREDUCTASES, N-DEMETHYLATING;

EID: 0035214454     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2001.119811     Document Type: Article

References (60)

1. Cyclosporine
2. A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine
3. Cyclosporine metabolism in human liver: Identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs
4. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat
5. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians
6. FK 506 renal toxicity and lack of detectable Cytochrome P-450 3A in the liver graft of a patient undergoing liver transplantation
7. Characterization of human cytochrome P450 enzymes
8. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes
9. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test
10. Optimization of cyclosporine therapy in liver transplantation
11. First-pass metabolism of cyclosporin by the gut
12. Microemulsion technology in the reformulation of cyclosporine: The reason behind the pharmacokinetic properties of Neoral
13. Induction of immunosuppression by microemulsion cyclosporine in liver transplantation
14. A pilot study of immunosuppressive monotherapy in liver transplantation: Tacrolimus versus microemulsified cyclosporin
15. Therapeutic drug monitoring of cyclosporine and tacrolimus
16. max) correlate with freedom from liver graft rejection: Results of a prospective, randomized comparison of Neoral and Sandimmune for liver transplantation (NOF-8)
17. Comparison of Neoral dose monitoring with cyclosporine through levels versus 2-hr post-dose levels in stable liver transplant patients
18. Cyclosporin toxicity at therapeutic blood levels and cytochrome P-450 IIIA
19. Central nervous system toxicity after liver transplantation. The role of cyclosporine and cholesterol
20. Optimization of cyclosporine therapy in renal transplantation by a pharmacokinetic strategy
21. Lake Louise Consensus Conference on cyclosporin monitoring in organ transplantation: Report of the consensus panel
22. Methodological and clinical aspects of cyclosporin monitoring: Report of the Association of Clinical Biochemists Task Force
23. Relationship between graft cytochrome P-450 3A content and early morbidity after liver transplantation
24. Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients
25. In vivo function tests of hepatic drug-oxidizing capacity in patients with liver disease
26. P450 3A activity and cyclosporine dosing in kidney and heart transplant recipients
27. Erythromycin breath test predicts oral clearance of cyclosporine in kidney transplant recipients
28. Importance of cytochrome P-450IIIA activity in determining dosage and blood levels of FK 506 and cyclosporine in liver transplant recipients
29. The erythromycin breath test selectively measures P450IIIA in patients with severe liver disease
30. Clinical use of FK 506 in liver transplantation
31. Preparation and properties of partially purified cytochrome P-450 and reduced nicotinamide adenine dinucleotide phosphate-cytochrome P-450 reductase from rabbit liver microsomes
32. A simplification of the protein assay method of Lowry et al. which is more generally applicable
33. Cleavage of structural proteins during the assembly of the head of bacteriophage T4
34. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications
35. Distribution of cytochromes P-450, cytochrome b5, and NADPH-cytochrome P-450 reductase in an entire human liver
36. Potential use of pharmacological markers to quantitatively assess liver function during liver transplantation surgery
37. The mechanism of cyclosporine toxicity induced by clarithromycin
38. Prediction of interpatient and intrapatient variation in OG 37-325 dosing requirements by the erythromycin breath test. A prospective study in renal transplant recipients
39. The erythromycin breath test predicts the clearance of midazolam
40. Comparison of levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples
41. Foreign compound metabolism studies with human liver obtained as surgical waster. Relation to donor characteristics and effects of tissue storage
42. Comparison of urinary 6-beta-cortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity
43. The human cytochrome P450 3A locus. Gene evolution by capture of downstream exons
44. Identification of a polymorphically expressed member of the human cytochrome P-450III family
45. Detection of CYP3A5 allelic variant: A candidate for the polymorphic expression of the protein?
46. No ethnic difference between Caucasian and Japanese hepatic samples in the expression frequency of CYP3A5 and CYP3A7 proteins
47. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3)
48. Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: Comparison of Ki values and impact of CYP3A5 expression
49. Expression of cytochrome P450 3A5 in Escherichia coli: Effects of 5′ modification, purification, spectral characterization, reconstitution conditions, and catalytic activities
50. CYP3A4 drug interactions: Correlation of 10 in vitro probe substrates
51. Roles of cytochrome b5 in the oxidation of testosterone and nifedipine by recombinant cytochrome P450 3A4 and by human liver microsomes
52. Role of phospholipids in reconstituted cytochrome P450 3A form and mechanism of their activation of catalytic activity
53. 14C]-erythromycin
54. Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men
55. Comparison of the dapsone recovery ratio and the erythromycin breath test as in vivo probes of CYP3A activity in patients with rheumatoid arthritis receiving cyclosporine
56. Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A
57. Mdr1 limits CYP3A metabolism in vivo
58. Early assessment of transplanted liver function: Lignocaine clearance test (MEGX)
59. A pilot study of indocyanine green clearance as an early predictor of graft function
60. Acute liver allograft rejection and liver function: Quantitative evaluation using the [14C]aminopyrine breath test